Shares of Regeneron Pharmaceuticals Inc. slipped 4.06% to $634.14 Tuesday, on what proved to be an all-around favorable ...
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
21d
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...
This was the stock's third consecutive day of losses.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE ...
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.
EDT Regeneron (REGN) down 3% after appeals court decision in Amgen (AMGN) patent fightLight Up your Portfolio with Spark:Easily identify ...
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback